V. Vandersleyen

C-reactive protein as a biomarker for immune-related adverse events in melanoma patients treated with immune checkpoint inhibitors in the adjuvant setting

B. Neyns, S. Aspeslagh, G. Awada, 2021, Melanoma research.

A clinicopathological description of COVID‐19‐induced chilblains (COVID‐toes) correlated with a published literature review

F. Feoli, A. Kolivras, A. Marneffe, 2021, Journal of cutaneous pathology.

A Synopsis of Serum Biomarkers in Cutaneous Melanoma Patients

J. Baurain, F. Cornélis, N. van Baren, 2012, Dermatology research and practice.

Low-Dose Nivolumab with or without Ipilimumab as Adjuvant Therapy Following the Resection of Melanoma Metastases: A Sequential Dual Cohort Phase II Clinical Trial

K. Willard-Gallo, B. Neyns, P. Kristanto, 2022, Cancers.

Which medical disciplines diagnose and treat melanoma in Europe in 2019? A survey of experts from melanoma centres in 27 European countries

R. Karls, A. Lallas, J. Paoli, 2020, Journal of the European Academy of Dermatology and Venereology : JEADV.

Vemurafenib‐associated Dupuytren‐ and Ledderhose palmoplantar fibromatosis in metastatic melanoma patients

B. Neyns, J. Gutermuth, S. Wilgenhof, 2016, Journal of the European Academy of Dermatology and Venereology.